🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Placebo to glycopyrronium

Found 62 matching trials

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

PHASE2

The overall objective of this study was to assess the efficacy and safety o...

Status

Completed

Location

Pearl Investigative Site

Start Date

2015-01-28

Trial ID

NCT03256552

Treatments Being Tested

Glycopyrronium MDI 28.8 micrograms Glycopyrronium MDI 14.4 micrograms Glycopyrronium MDI 7.2 micrograms Placebo MDI

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study was designed to investigate the 1 year efficacy and safety of th...

Status

Completed

Location

Novartis Investigative Site

Start Date

2009-06

Trial ID

NCT00929110

Treatments Being Tested

Glycopyrronium bromide Placebo to glycopyrronium bromide Tiotropium

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

PHASE3

The purpose of the study is to provide long term safety data of NVA237. Thi...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01697696

Treatments Being Tested

NVA237 Long-acting beta 2-agonist (LABA)Placebo

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to evaluate the efficacy of Fixed Combination ...

Status

Completed

Location

Medical Center Convex EOOD

Start Date

2018-06-15

Trial ID

NCT03590379

Treatments Being Tested

CHF 5993 DPI CHF5993 pMDI CHF 1535 pMDI Placebo DPI Placebo pMDI

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

PHASE1

The study is being conducted to compare the pharmacokinetic (PK) of BDP (an...

Status

Completed

Location

SGS Belgium NV - Clinical Pharmacology Unit

Start Date

2023-04-24

Trial ID

NCT05898984

Treatments Being Tested

Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

PHASE3

This study will investigate the effect of Budesonide, Glycopyrronium, and F...

Status

Completed

Location

Research Site

Start Date

2023-10-24

Trial ID

NCT06067828

Treatments Being Tested

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Treatment B: Budesonide and Formoterol Fumarate Treatment C : Placebo

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

PHASE2

The purpose of this trial is to characterize the bronchodilator effects and...

Status

Completed

Location

Novartis Investigative Site

Start Date

2017-05-04

Trial ID

NCT03137784

Treatments Being Tested

NVA237 (glycopyrronium bromide)Placebo

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

PHASE3

This study will assess the efficacy, safety and tolerability of indacaterol...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-12

Trial ID

NCT01712516

Treatments Being Tested

QVA149 QAB149 NVA237 Placebo

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

PHASE2

This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cros...

Status

Completed

Location

University of Utah MidValley Dermatology

Start Date

2021-09-27

Trial ID

NCT04924036

Treatments Being Tested

glycopyrronium cloths Placebo

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

PHASE4

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3...

Status

Completed

Location

PAREXEL International GmbH Early Phase Clinical Unit Berlin

Start Date

2021-10-28

Trial ID

NCT05097014

Treatments Being Tested

CHF5993 CHF1535 Matched placebo

Previous Next